309 related articles for article (PubMed ID: 33615803)
1. Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.
Maeda A; Yoshida H; Inoue H; Ejiri M; Yamaguchi S; Kushihara H; Yamamoto Y; Ando Y; Sato Y; Tashiro Y; Hasegawa A; Takahara Y; Mizutani M; Oze I; Shimizu J
Ann Palliat Med; 2021 Mar; 10(3):2699-2708. PubMed ID: 33615803
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2021 Jul; 21(1):832. PubMed ID: 34281514
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
7. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
Fonte C; Fatigoni S; Roila F
Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
[TBL] [Abstract][Full Text] [Related]
9. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial.
An Y; Zhang Z; Gu M; Zhao J; Jiang C; Zhao L; Jiang Y; Li H; Liu G; Jin G; Li Q
Curr Pharm Des; 2023; 29(23):1867-1874. PubMed ID: 37539930
[TBL] [Abstract][Full Text] [Related]
10. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
Sakai C; Shimokawa M; Iihara H; Fujita Y; Ikemura S; Hirose C; Kotake M; Funaguchi N; Gomyo T; Imai H; Hakamata J; Kaito D; Minato K; Arai T; Kawazoe H; Suzuki A; Ohno Y; Okura H
Oncologist; 2021 Jun; 26(6):e1066-e1072. PubMed ID: 33811782
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.
Chanthawong S; Subongkot S; Sookprasert A
J Med Assoc Thai; 2014 Mar; 97(3):349-55. PubMed ID: 25123016
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.
Radhakrishnan V; Pai V; Rajaraman S; Mehra N; Ganesan T; Dhanushkodi M; Perumal Kalaiyarasi J; Rajan AK; Selvarajan G; Ranganathan R; Karunakaran P; Sagar TG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28532. PubMed ID: 32568452
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.
Monson T; Greer D; Kreikemeier E; Liewer S
J Oncol Pharm Pract; 2020 Jun; 26(4):918-922. PubMed ID: 31635549
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Maeda A; Ura T; Asano C; Haegawa I; Nomura M; Komori A; Narita Y; Taniguchi H; Kadowaki S; Muro K; Horio Y; Yoshida T; Oze I; Kajita M; Mizutani A
Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
Navari RM; Pywell CM; Le-Rademacher JG; White P; Dodge AB; Albany C; Loprinzi CL
JAMA Oncol; 2020 Jun; 6(6):895-899. PubMed ID: 32379269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]